Pfizer unit Meridian under civil investigation by U.S. Attorney
Reprints
(Reuters) — Pfizer Inc. said on Thursday it received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at its Meridian Medical Technologies site.
Pfizer, in a regulatory filing, said it would be producing records in response to the civil investigative demand from the U.S. Attorney's office for the Southern District of New York.
Meridian, a unit of Pfizer that manufactures EpiPen injectors used to deliver an emergency allergy antidote, has been hit by a series of manufacturing problems in recent years. Mylan NV, which markets EpiPens, has recalled tens of thousands of the devices after complaints that some had failed to activate.
In 2017, Meridian had received a warning letter from the Food and Drug Administration. The FDA said Meridian had failed to thoroughly investigate product failures, including EpiPen products that were associated with patient deaths and severe illnesses. It said the company failed to take corrective actions until FDA's inspection.
Meridian produces all EpiPens sold globally at a single plant near St. Louis.
EpiPen auto-injectors deliver a dose of epinephrine in the event of severe allergic reaction, such as to bee stings or exposure to peanuts.
Read Next
-
INTEL, IBM AND PFIZER INVEST IN SUPPLIER DIVERSITY
Intel, IBM and Pfizer have pledged to invest $300 million in women- and minority-owned businesses over the next three years as part of the companies’ supplier diversity initiatives. “Supplier diversity adds tremendously to our competitive advantage while stimulating growth in a global marketplace,” notes Barbara Whye, Intel’s chief diversity and inclusion officer. In 2015, Intel announced it was boosting spending with diverse suppliers to $1 billion annually by the year 2020.
Related Stories
Most Read in Risk Management
-
5. Chubb readies $350 million payout tied to Baltimore bridge collapse
-
6. Companies must fight fire with fire to combat nuclear verdicts: Expert
